Trinity Biotech (TRIB) Competitors $0.77 0.00 (0.00%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.78 +0.01 (+1.12%) As of 02/21/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends TRIB vs. IMMX, LTRN, RPTX, PRLD, RNTX, KALA, CNTB, CELU, XLO, and DYAIShould you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include Immix Biopharma (IMMX), Lantern Pharma (LTRN), Repare Therapeutics (RPTX), Prelude Therapeutics (PRLD), Rein Therapeutics (RNTX), KALA BIO (KALA), Connect Biopharma (CNTB), Celularity (CELU), Xilio Therapeutics (XLO), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. Trinity Biotech vs. Immix Biopharma Lantern Pharma Repare Therapeutics Prelude Therapeutics Rein Therapeutics KALA BIO Connect Biopharma Celularity Xilio Therapeutics Dyadic International Immix Biopharma (NASDAQ:IMMX) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking. Does the media refer more to IMMX or TRIB? In the previous week, Immix Biopharma's average media sentiment score of 0.00 equaled Trinity Biotech'saverage media sentiment score. Company Overall Sentiment Immix Biopharma Neutral Trinity Biotech Neutral Which has preferable earnings and valuation, IMMX or TRIB? Immix Biopharma has higher earnings, but lower revenue than Trinity Biotech. Immix Biopharma is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmix BiopharmaN/AN/A-$15.43M-$0.85-2.07Trinity Biotech$56.83M0.24-$24.02M-$2.26-0.34 Do institutionals and insiders hold more shares of IMMX or TRIB? 11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 48.9% of Immix Biopharma shares are held by insiders. Comparatively, 8.2% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community believe in IMMX or TRIB? Trinity Biotech received 324 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 71.58% of users gave Trinity Biotech an outperform vote. CompanyUnderperformOutperformImmix BiopharmaOutperform Votes11100.00% Underperform VotesNo VotesTrinity BiotechOutperform Votes33571.58% Underperform Votes13328.42% Do analysts prefer IMMX or TRIB? Immix Biopharma currently has a consensus price target of $7.00, indicating a potential upside of 297.73%. Given Immix Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Immix Biopharma is more favorable than Trinity Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is IMMX or TRIB more profitable? Immix Biopharma has a net margin of 0.00% compared to Trinity Biotech's net margin of -34.39%. Trinity Biotech's return on equity of 0.00% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Immix BiopharmaN/A -102.68% -80.89% Trinity Biotech -34.39%N/A -21.37% Which has more risk and volatility, IMMX or TRIB? Immix Biopharma has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. SummaryImmix Biopharma beats Trinity Biotech on 8 of the 15 factors compared between the two stocks. Get Trinity Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRIB vs. The Competition Export to ExcelMetricTrinity BiotechDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.87M$2.19B$5.77B$8.98BDividend YieldN/A0.75%4.78%3.85%P/E Ratio-0.345.0426.4618.82Price / Sales0.2487.03453.2580.30Price / CashN/A15.7944.0437.47Price / Book-0.243.287.634.64Net Income-$24.02M-$65.73M$3.18B$245.69M7 Day Performance1.11%-3.90%-1.91%-2.66%1 Month Performance-0.56%-8.97%-0.19%-2.15%1 Year PerformanceN/A-15.59%16.70%12.90% Trinity Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRIBTrinity Biotech0.4042 of 5 stars$0.77flatN/AN/A$13.87M$56.83M0.00480IMMXImmix Biopharma2.6059 of 5 stars$1.98-0.5%$7.00+253.5%-41.1%$54.47MN/A-2.339LTRNLantern Pharma0.4666 of 5 stars$5.01+3.7%N/A+10.2%$54.01MN/A-2.8120News CoverageNegative NewsRPTXRepare Therapeutics3.001 of 5 stars$1.27+5.8%$7.00+451.2%-79.0%$53.99M$51.13M-0.64180Upcoming EarningsPRLDPrelude Therapeutics2.2657 of 5 stars$0.97+2.1%$4.00+312.4%-77.0%$53.38MN/A-0.54120RNTXRein TherapeuticsN/A$2.44+3.8%N/AN/A$52.88MN/A-0.789Gap DownKALAKALA BIO3.9589 of 5 stars$8.38+8.0%$15.00+79.0%-7.0%$51.03M$3.89M-0.6730CNTBConnect Biopharma2.9772 of 5 stars$0.92-4.9%$8.00+767.3%-24.3%$50.96MN/A0.00110CELUCelularity0.9873 of 5 stars$2.14+4.4%N/A-61.1%$50.95M$48.20M0.00220XLOXilio Therapeutics3.2532 of 5 stars$1.14-11.6%$4.00+250.9%+63.2%$50.11M$4.62M-0.6670High Trading VolumeDYAIDyadic International1.8103 of 5 stars$1.69flat$6.00+255.0%-2.0%$50.01M$2.90M-7.357Gap Up Related Companies and Tools Related Companies Immix Biopharma Competitors Lantern Pharma Competitors Repare Therapeutics Competitors Prelude Therapeutics Competitors Rein Therapeutics Competitors KALA BIO Competitors Connect Biopharma Competitors Celularity Competitors Xilio Therapeutics Competitors Dyadic International Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRIB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trinity Biotech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Trinity Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
